SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 509.63 |
| Enterprise Value ($M) | 486.58 |
| Book Value ($M) | 88.58 |
| Book Value / Share | 2.10 |
| Price / Book | 5.75 |
| NCAV ($M) | 78.72 |
| NCAV / Share | 1.87 |
| Price / NCAV | 6.47 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.13 |
| Return on Assets (ROA) | -0.59 |
| Return on Equity (ROE) | -0.67 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.44 |
| Current Ratio | 5.44 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 104.10 |
| Assets | 113.97 |
| Liabilities | 25.39 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | TCG Crossover GP I, LLC | 3.20 | -50.17 | |
| 13G | Adage Capital Partners Gp, L.l.c. | 6.87 | ||
| 13D/A | Frazier Life Sciences Public Fund, L.P. | 8.90 | 2.95 | |
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 14.00 | 35.01 | |
| 13G/A | Tang Capital Partners Lp | 9.96 | 7.63 | |
| 13G | Vanguard Group Inc | 5.15 | ||
| 13G/A | Suvretta Capital Management, Llc | 7.80 | 49.41 | |
| 13G | Saturn V Capital Management LLC | 4.10 | ||
| 13G/A | Fmr Llc | 0.15 | -96.11 | |
| 13G | BlackRock Inc. | 6.50 | 42.58 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 32,047 | 179,464 | 17.86 | |
| 44,994 | 86,524 | 52.00 | |
| 19,270 | 60,103 | 32.06 | |
| 30,972 | 67,997 | 45.55 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| IVVD – Invivyd, Inc. | IXHL – Incannex Healthcare Inc. |
| JANX – Janux Therapeutics, Inc. | KOD – Kodiak Sciences Inc. |
| KROS – Keros Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io